BioNote
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BioNote makes rapid diagnostic test kits and reagents used to detect diseases in animals, relying on its own technology for producing recombinant antigens and antibodies, the biological building blocks that make diagnostic tests work.
Its products are supplied to distributors and affiliated partners in multiple countries. Listed on KOSPI, Korea's main stock exchange, the company is also expanding its core biological materials, antigens, antibodies, and enzymes, into the supply chain for human in-vitro diagnostic (IVD) reagents, broadening beyond its veterinary roots.
Summary is AI-generated and may contain errors · figures from DART filings
BioNote in five facts
What does BioNote do?
BioNote makes rapid diagnostic test kits and reagents used to detect diseases in animals, relying on its own technology for producing recombinant antigens and antibodies, the biological building blocks that make diagnostic tests work.
Where is BioNote listed and in which sector?
BioNote (Korean name: 바이오노트) trades under KRX code 377740 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is BioNote?
Its market capitalisation was US$350.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were BioNote's latest annual revenue and operating profit?
For fiscal year 2025, BioNote reported revenue of US$89.3M, operating profit of US$12.6M and a net loss of US$66M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 15.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
BioNote filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$25.6M (+12.23% year on year), operating profit of US$5.95M (+33.21% year on year) and net income of US$6.38M (−89.27% year on year).
Earnings · Aug 6 - Operating results (consolidated) (preliminary) (fair disclosure)
BioNote filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$21.9M (+14.49% year on year), operating profit of US$4.26M (+35.16% year on year) and net income of US$27.7M (+925.36% year on year).
Earnings · May 13 - [Amended] Cash/in-kind dividend decision
BioNote updated its declared cash dividend of US$0.15 per share, equal to about 3.82% of the recent share price.
Dividend · Mar 11 · 2 versions - Operating results (consolidated) (preliminary) (fair disclosure)
BioNote filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$19.4M (+13.05% year on year), operating profit of US$583K (−66.97% year on year) and a net loss of US$137M (from a profit a year earlier).
Earnings · Feb 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
BioNote reported consolidated results for FY2025: revenue of US$82.2M (+15.12% year on year), operating profit of US$11.6M (+36.76% year on year) and a net loss of US$62.8M (from a profit a year earlier).
Earnings · Feb 25